Clinical trial
Phase III Randomized Study of Interferon Gamma in Children With Severe…
NCT00004402 · FDA Office of Orphan Products Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00004402 |
|---|---|
| Title | Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis |
| Lead sponsor | FDA Office of Orphan Products Development, U.S. Fed |
| Collaborators | Medical University of South Carolina |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteopetrosis |
| Intervention type | Drug |
| Interventions | calcitriol, interferon gamma |
| Enrollment | 30 |
| Start date | Nov 1, 1999 |
| Completion | Jun 1, 2000 |
| First posted | Oct 19, 1999 |
| Last update posted | Mar 25, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: